Gastroesophageal Reflux Disease Market Size, Epidemiology, Trends, and Forecast 2025

NEW YORK - June 9, 2025 - PRLog -- The 7 major gastroesophageal reflux disease markets size reached a value of USD 5.1 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 6.4 Billion by 2035, exhibiting a growth rate (CAGR) of 2% during 2025-2035.

In 2025, the gastroesophageal reflux disease (GERD) market will grow steadily, fueled by increasing incidence and swift technological innovation. GERD, characterized by chronic acid reflux and heartburn, continues to afflict a significant percentage of the worldwide population, leading to mounting demand for effective therapies and sophisticated diagnostics.

Increasing Incidence and Awareness

Global GERD burden is increasing, driven by lifestyle factors like increased intake of processed foods, weight gain, and lack of physical activity. Urban lifestyle and eating habits correlate with increased GERD prevalence in North America and East Asia, and the 60–70 year old age group is especially at risk. Increased awareness and improved access to care are leading more individuals to be diagnosed, increasing market visibility and treatment demand.

Market Growth and Regional Dynamics

The worldwide GERD therapeutics market was worth approximately USD 5.1 billion in 2024, with expected growth to mid-decade demonstrating around 2–2.5% yearly increases. North America remains the market leader based on mature care systems, lifestyle-related risk factors, and widespread use of new treatments. Europe is second, receiving support from care pathways, whereas Asia–Pacific is the fastest-growing area—urbanization, increased income, and growing access to healthcare are behind the demand.

Technological Changes and Patient Availability

The last few years have witnessed a sharp increase in the use of endoscopic therapies and high-tech diagnostics, along with more telemedicine services, at-home pH tests, and intelligent health monitoring devices—therapeutic innovation is keeping pace with digital change.

But, still, there are barriers. These consist of cost constraints, unpredictable reimbursement for new procedures, and lack of access to state-of-the-art care in low-income areas. Closing these gaps will be essential to making equitable use of emerging GERD solutions.

Request for a sample of this report: https://www.imarcgroup.com/gastroesophageal-reflux-disease-market/requestsample

Competitive Landscape with key players:

The competitive landscape of the gastroesophageal reflux disease markets size (https://www.imarcgroup.com/gastroesophageal-reflux-diseas...)  has been studied in the report with the detailed profiles of the key players operating in the market.

1. AstraZeneca/Mitsubishi Tanabe Pharma Corporation

2. Takeda

3. Takeda

4. AstraZeneca

5. Eisai

Explore the Full Report with TOC: https://www.imarcgroup.com/request?type=report&id=8331&flag=A

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.